16 February 2018 - - Milford, Massachusetts-based life sciences company SeraCare Life Sciences has expanded its suite of clinical genomics development, validation, and QC tools with the launch of dedicated copy number variations (CNV) reference materials for NGS assays - Seraseq Breast CNV Mix, and Seraseq Lung and Brain CNV Mix, the company said.
CNVs are DNA segments present at a variable copy number in comparison to a normal genome. Cells that are affected by aberrant copy number changes for certain cancer-associated genes may experience disruption of normal cellular function and, ultimately, tumorigenesis.
Reference materials that analyse for CNVs allow for a complete and comprehensive variant assessment of DNA-based tumor profiling and diagnostic molecular assays beyond SNVs and indels.
These unique products were precisely quantified using highly sensitive digital PCR assays to analyze amplifications of EGFR, MET, FGFR3, MYC, ERBB2, and MYCN genes at +3, +6, and +12 copies against a single well-characterized genomic background (GM24385).
SeraCare tools and technologies provide assurance of the safe, effective, and accurate performance of diagnostic assays and establish a framework for regulating, compiling, and interpreting data from precision diagnostics.
Its portfolio includes a range of products such as quality control technologies, disease-state specimens and tissues for research and development, processed biological materials, and immunoassay reagents.